Table 1 Basic characteristics of patients with pancreatic tumors stratified by tumor histology

Age at diagnosis, n (%)

< 0.001

≤ 14-year-old

21 (33.3%)

19 (28.8%)

20 (90.9%)

24 (54.5%)

> 14-year-old

42 (66.7%)

47 (71.2%)

2 (9.1%)

20 (45.5%)

Gender, n (%)

< 0.001

Female

57 (90.5%)

35 (53%)

10 (45.5%)

26 (59.1%)

Male

6 (9.5%)

31 (47%)

12 (54.5%)

18 (40.9%)

Race, n (%)

0.569

White

47 (74.6%)

50 (75.8%)

14 (63.6%)

35 (79.5%)

Others

16 (25.4%)

16 (24.2%)

8 (36.4%)

9 (20.5%)

Primary sites, n (%)

0.024

Head

21 (33.3%)

19 (28.8%)

8 (36.4%)

25 (56.8%)

Body

7 (11.1%)

5 (7.6%)

2 (9.1%)

6 (13.6%)

Tail

21 (33.3%)

17 (25.8%)

4 (18.2%)

3 (6.8%)

Unknown

14 (22.2%)

25 (37.9%)

8 (36.4%)

10 (22.7%)

Grade, n (%)

< 0.001

Low/moderate (I/II)

20 (31.7%)

28 (42.4%)

0 (0%)

7 (15.9%)

Poor/undifferentiated (III/IV)

1 (1.6%)

4 (6.1%)

1 (4.5%)

5 (11.4%)

Unknown

42 (66.7%)

34 (51.5%)

21 (95.5%)

32 (72.7%)

Tumor size (cm), n (%)

0.065

≤ 5

7 (11.1%)

17 (25.8%)

4 (18.2%)

10 (22.7%)

> 5

19 (30.2%)

9 (13.6%)

5 (22.7%)

4 (9.1%)

Unknown

37 (58.7%)

40 (60.6%)

13 (59.1%)

30 (68.2%)

SEER stage, n (%)

< 0.001

Localized

45 (71.4%)

29 (43.9%)

7 (31.8%)

14 (31.8%)

Regional

16 (25.4%)

10 (15.2%)

4 (18.2%)

11 (25%)

Distant

2 (3.2%)

27 (40.9%)

11 (50%)

19 (43.2%)

Surgery, n (%)

< 0.001

Yes

59 (93.7%)

38 (57.6%)

16 (72.7%)

23 (52.3%)

No

4 (6.3%)

28 (42.4%)

6 (27.3%)

21 (47.7%)

Lymph nodes removed, n (%)

< 0.001

Yes

44 (69.8%)

26 (39.4%)

6 (27.3%)

7 (15.9%)

No

19 (30.2%)

40 (60.6%)

16 (72.7%)

37 (84.1%)

Chemotherapy, n (%)

< 0.001

Yes

2 (3.2%)

20 (30.3%)

11 (50%)

27 (61.4%)

No

61 (96.8%)

46 (69.7%)

11 (50%)

17 (38.6%)

Treatment regimens, n (%)

< 0.001

No treatment

4 (6.3%)

11 (16.7%)

2 (9.1%)

4 (9.1%)

Surgery alone

57 (90.5%)

35 (53%)

9 (40.9%)

13 (29.5%)

Chemotherapy alone

0 (0%)

17 (25.8%)

4 (18.2%)

17 (38.6%)

Surgery plus chemotherapy

2 (3.2%)

3 (4.5%)

7 (31.8%)

10 (22.7%)